Kornimate/medical-research-clean huggingface dataset:
association of leucocyte telomere length with dpas score in skin aging

Conditions: Aging; Skin Laxity

Summary: the goal is to know the profile of photoaging based on clinical examination, dermoscopic photoaging scale and leucocyte telomere length the main questions of research are: * what is the profile of photoaging based on clinical examination results in skin aging * what is the profile of photoaging based on dpas score in skin aging * what is the profile of leucocyte telomere length in skin aging participants are female and male with the age of 29-31 years old and 59-61 years old. they will be examined by dermatovenereologist and will be photographed in 5 positions, they will get dermocopy on forehead, right cheek , left cheek, and chin, and their blood will be drawn about 10 ml in order to get the profile of leucocyte telomere length

skin aging is a process of deterioration in the physiological structure and function of the skin that significantly increases in the 4th and 5th decades of life. skin aging is a combination of physiological and pathological aging. physiological change cannot be avoided and mandatory for everyone, pathological aging ir extrinsic aging is an abnormal skin condition caused by cigarettes, pollution and ultraviolet (uv). in general, the clinical characteristics of skin aging consist of pigmentation changes, hydration disorders, the appearance of wrinkles and skin tumors. the photoaging assessment was first proposed in 1996 by dr. richard glogau, the glogau scale assesses photoaging based on clinical assessment grouped into 4 categories, namely types i, ii, iii, and iv,where each type is graded by the severity of wrinkles, namely from mild, moderate, advanced, and severe. isik et al. developed an instrument for quantitative skin aging assessment using dermoscopy. this examination is non-invasive and is expected to provide a more objective assessment. there are four facial regions assessed in the dpas score calculation: forehead, right cheek, left cheek, and chin. the sum of the scores of the four regions is assessed based on 11 parameters, with a maximum final score of 44. telomeres are repetitive dna-protein complexes located at the ends of chromosomes of eukarotic cells, and their function is to maintain chromosome stability during cell division, by protecting chromosomes from degradation and fusion. many factors affect telomere length, such as body mass index, hormonal therapy, antioxidant intake, chronic diseases, and gender. research by son et al. found that telomere length shortening was validated to increase the odds of skin aging (or=0.96, 95% ci: 0.9332-0.99566, p= 0.03) telomeres are closely linked to cellular aging, especially in dermal cells and telomere shortening in skin fibroblasts may lead to epidermal aging and barrier function defectcs.

Eligibility criteria:
inclusion criteria: * female and male (age 29-31 years old and 59-61 years old * signs of aging exclusion criteria: * pregnant or breastfeeding * have disease or genetic problem

Keywords: dermoscopy dermoscopic photoaging scale (dpas) glogau scale leucocyte telomere length (ltl) photoaging skin aging telomere ultraviolet (uv)
sexual function changes in high-risk pregnancies

Conditions: Sexual Dysfunctions, Psychological; High Risk Pregnancy; Sexual Behavior

Summary: sexual function changes in high-risk pregnancies

background and aim: sexual functions generally decrease during pregnancy, and high-risk pregnancies are more severe clinical conditions that cause couples to reduce or abstain entirely from their intimacy. however, the evidence on the sexual functions in high-risk pregnancies is scarce. therefore, this study aimed to evaluate the sexual function changes in high-risk pregnancies compared to normal pregnancies. methods: a total of 200 pregnant women (100 women in high-risk pregnancy and normal pregnancy groups each) were included. demographic and obstetric data were collected, and participants completed the female sexual function index (fsfi).

Eligibility criteria:
inclusion criteria: study grup pregnant women who ; followed up for hrp in the second trimester (14th to 28th gestational weeks), between 20 to 40 years old, followed up at our perinatology department with a diagnosis of iugr, cholestasis, diabetes, preeclampsia, fetal anomaly control grup admitted for routine second-trimester ultrasonography assessment but with no risk for pregnancy exclusion criteria: pregnant women who ; younger than 20 or older than 40 years of age, gestation in the 1st or 3rd trimester, presence of psychiatric or chronic disorders like rheumatic or heart diseases, -

Keywords: sexual dysfunction, high-risk pregnancy, fsfi, quality of life
safety, tolerability, and efficacy of cariprazine in participants with bipolar depression

Conditions: Depression, Bipolar

Summary: the objective of this study was to evaluate the efficacy, safety, and tolerability of cariprazine relative to placebo for the treatment of participants with bipolar depression.


Eligibility criteria:
inclusion criteria: * participants who have provided informed consent prior to any study specific procedures. * participants currently meeting the diagnostic and statistical manual of mental disorders, fourth edition, text revision (dsm-iv-tr) criteria for bipolar i disorder as confirmed by the structured clinical interview (scid) with a current with a current major depressive episode of at least 4 weeks and not exceeding 12 months in duration. * participants with normal physical examination, laboratory, vital signs, and/or echocardiogram (ecg). * verified previous manic or mixed episode. * participants with a total hamilton rating scale for depression (hamd)-17 score ≥ 20. * participants with a hamd-17 item 1 score ≥ 2. * participants with a clinical global impression of severity (cgi-s) score ≥ 4. exclusion criteria: * participants with a dsm-iv-tr diagnosis of an axis i disorder other than bipolar i disorder that was the primary focus of treatment within the previous 6 months. * women who are pregnant or breast feeding * participants with young mania rating scale (ymrs) total score \> 10 * participants who have dementia, mental retardation, schizophrenia/schizoaffective disorder.

Keywords: bipolar i disorder bipolar depression depression bipolar disorder
oral hygiene self-efficacy in patients with grief

Conditions: Grief

Summary: to investigate the effect of oral hygiene self-efficacy in patients with grief (g) and complicated grief (cg)

aim: to investigate the effect of oral hygiene self-efficacy in patients with grief (g) and complicated grief (cg). study design: randomized controlled trial. setting: institute of psychiatry-fmusp (ipq-fmusp). subjects: cases: patients seeking for treatment or under treatment for cg (group 1), and patients with normal grief (group 2). controls: hospital staff at the hc-fmusp or volunteers from a list of other studies conducted at the ipq-fmusp (group 3). method. psychiatric evaluation: structured clinical interview (scid), texas revised inventory of grief (trig) and clinical interview. intervention: instruction of oral hygiene. dental evaluation: probing depth, clinical attachment level, bleeding on probing, and frequency of plaque at six sites per tooth. procedures: all participants will complete the psychiatry and dental evaluation at baseline. the bleeding on probing and frequency of plaque will be recorded at baseline, once a week (1 month follow-up) and at 3 months. the probing depth and clinical attachment level will be recorded at baseline and at 3 months. after 3 months, the patients will be referred for dental treatment.

Eligibility criteria:
inclusion criteria: * diagnosis of grief or complicated grief * informed consent signature exclusion criteria: * patients with severe major depressive disorder at risk for suicide; * substance abuse or dependence, * psychotic disorders * systemic alteration that precludes periodontal clinical examination

Keywords: grief, periodontal disease
the effects of robot-assisted gait training(ragt) on patients with burn

Conditions: Burns

Summary: this study aimed to elucidate the efficacy and investigate the mechanism of motor recovery after ragt on patients with lower extremity burn. to investigate ragt effects, we compare the results of rgat group to the results of matched conventional(con) rehabilitation group.

gait enables individuals to move forward and is considered a natural skill. however, gait disturbances are very common in patients with burn injury. major causes of functional impairment are pain and joint contractures. contractures at the lower extremities such as the hip, knee, and ankle significantly limit gait. recent studies focused on the application of robot-assisted gait training (ragt). this single-blinded, randomized, controlled trial involved 40 patients with lower extremity burns. patients were randomized into a ragt or a con group. subar® (cretem, korea) is a wearable robot with a footplate that assists patients to perform voluntary muscle movements. ragt enables training of automatically programmed normal gait pattern. patients underwent 30 min of ragt using subar® and conventional exercise rehabilitation each for 30 min once a day for 5 days a week for 12 weeks. the con group focused on gait training such as passive rom exercise, weight bearing training, manual lymphatic drainage, and hypertrophic scar care for 60 min once a day for 5 days a week for 12 weeks. a wearable functional near-infrared spectroscopy (fnirs) device has been developed for studying cortical hemodynamics. changes in cortical activity has not previously been documented in patients with burn injury. cortical activity was measured by evaluating relative changes in oxyhemoglobin level. the nirst analysis tool v2.1 was utilized to analyze fnirs data in a matlab environment. functional scores of functional ambulation category (fac), 6-minute walking test (6mwt) distances, and numeric rating scale (nrs) scores of pain before and after 12 weeks ragt were measured. numeric rating scale (nrs) was used to rate the degree of subjective pain during gait movement: 0 points were assigned when no pain was noted, and unbearable pain was assigned 10 points. to evaluate functional recovery, fac scores and 6-minute walking test (6mwt) distances were measured. fac was evaluated based on six scales. scale 0 means that the patient cannot walk or can only walk with assistance of two people. scale 5 means that the patient can walk independently. we measured walking-related cortical activity using an fnirs device before and after 12 weeks ragt.

Eligibility criteria:
inclusion criteria: * the parients with lower extremity burn * ≤1 functional ambulation category (fac) score ≤ 3 exclusion criteria: * cognitive disorders * intellectual impairment before burn injury * serious cardiac dysfunction * problems with weight bearing due to unstable fractures * body weight ≥100 kg * severe fixed contracture * skin disorders that could be worsened by robot assisted gait training

Keywords: funcional near infrared spectroscopy robot-assisted gait training
efficacy and safety of parecoxib iv/im 40 mg vs placebo following sub muscular breast augmentation

Conditions: Pain, Postoperative

Summary: the present study aims to compare the pre-emptive analgesic efficacy of parecoxib 40 mg iv/im versus placebo on reducing postoperative acute pain following submuscular breast augmentation. additionally this study is being conducted to evaluate the safety and tolerability of parecoxib in this kind of procedure.


Eligibility criteria:
inclusion criteria: * female patients of any ethnic origin aged 18 years or over. * the patient is post-menopausal, surgically sterile, or using adequate contraception, not lactating, with a negative urine pregnancy test at screening, prior to administration of study medication. * the patient's preoperative health is graded as a class i or ii according to the asa physical status classification and on the basis of medical history and physical examination. exclusion criteria: * the patient has significant clinical signs and symptoms suggestive of renal or hepatic morbid conditions * the patient has a history of clinically significant hypersensitivity to any nsaids, cyclooxygenase inhibitors, analgesics or sulfa medications which has a cross sensitivity to the medications used in this study. * the patient used analgesics or other agents (antidepressants, sedating antihistamines or other sedatives, muscle relaxants, narcotics, or corticosteroids) during the four hours preceding the procedure that could confound the analgesic responses. * subjects with a history of established ischemic heart disease (e.g. myocardial infarction, stable angina, unstable angina), peripheral arterial disease and/or cerebrovascular disease (e.g. ischemic or hemorrhagic stroke, transient ischemic attack), as well as subjects with previous revascularization procedure to coronary, carotid, cerebral, renal, aortic or peripheral arterial vasculature
feasibility and pilot testing of group-based act for adolescents with functional somatic syndromes

Conditions: Functional Disorder

Summary: recurrent and impairing functional somatic syndromes (fss) are common in adolescents. despite a high need for care, empirically supported treatments are lacking for youth. the aim of the uncontrolled was to assess feasibility and treatment potential of group-based acceptance and commitment therapy (act) in a generic treatment approach for adolescents with multiple fss i.e. "act for health in adolescents" (ahead).


Eligibility criteria:
inclusion criteria: * bodily distress syndrome, multi-organ type of at least 12 months' duration * raised since early childhood in denmark or born by danish parents * understand, speak and read danish * moderate or severe impairment exclusion criteria: * acute psychiatric disorder demanding other treatment, or if the patient is suicidal. * a lifetime diagnosis of psychosis, mania or depression with psychotic symptoms (icd-10: f20-29, f30-31, f32.2, f33.3), serious cognitive deficits or developmental disorders such as mental retardation and autism (icd-10: f70, f84) * substance abuse of e.g. narcotics, alcohol or medication. * pregnancy at time of inclusion * not able to participate in group-based treatment, e.g. patients with severe adhd (icd-10: f90), severe social phobia (icd-10: f40.1) or conduct disorder (icd-10: f91)
validation of a remediation method for memory disorders using motor and emotional encoding in patients with alzheimer's disease

Conditions: Alzheimer Disease

Summary: memories are more robust when they are multitraced. this means that the more a piece of information is mediated by different sensory inputs, the more resistant it is to being forgotten. many works in the field of embodied cognition show that new learnings are better recalled over the long term when they are learned during body mobilization. other works show that musical stimulation could be a good way of eliciting physiological and emotional states more favorable to the memorization of new contents. however, to date, no studies have examined the positive effects of these two tools combined in alzheimer's disease. the investigators suggest that it is possible to optimize memory in alzheimer's disease by referring to their motor and emotional resources. the hypothesis is that information will be better recalled with multimodal enriched learning.

in a within subjects design, all patients take part in four conditions. in each condition, sentences describing actions will be displayed. in a control condition, they will be asked to read the sentence aloud; in a motor-only condition, they will also be asked to mime the sentence; in an emotional-only condition, they will be asked to read the sentence while listening to music; and in a dual condition, they will be asked to both mime and listen to music. immediately after each condition, they will realize a recognition task. the main criterion used in our statistical analyses will be the discrimination threshold.

Eligibility criteria:
inclusion criteria: * diagnosis of alzheimer's disease by one of the consulting physicians, neurologist and/or geriatrician of whom the patient has been informed. * early stage (mmse ≥ 22) * neuropsychological assessment within 6 months of inclusion. * affiliation with a social security scheme * age equal to or greater than 60 * french mother tongue * agreement to participate / signature of consent form exclusion criteria: * uncorrected perceptual disorders * other neurological or psychiatric history * inability to communicate * delusional or psychotic state * person unable to give informed consent * refusal to participate * participation in a study on a drug/medical device/care technique likely to affect cognitive functions

Keywords: alzheimer action memory musical memory
early versus ultra early surgical treatment of ruptured intracranial aneurysms

Conditions: Aneurysmal Subarachnoid Hemorrhage

Summary: the goal of this clinical trial is to determine the most effective timing for clipping in adults with ruptured intracranial aneurysms. it will also assess the safety of performing the surgery at different times of early period after the aneurysm has ruptured. the main questions it aims to answer are: 1. does ultra-early surgical intervention ( less than 24 hours of rupture) improve survival rates compared to delayed surgery (24 to 72 hours after rupture)? 2. what are the complication rates associated with early versus delayed surgical intervention? researchers will compare clipping in ultra-early period to surgery in early period to see if timing affects the outcomes for treating ruptured intracranial aneurysms. participants will: * be randomly assigned to undergo surgical clipping either within 24 hours of rupture or between 24 hours to 72 hours after the rupture. * visit the clinic for follow-up assessments at 1 month, 3 months, 6 months, and 12 months post-surgery. * keep a diary of their symptoms, neurological function, and any complications they experience post-surgery.


Eligibility criteria:
inclusion criteria: * aneurysmal subarachnoid hemorrhage * patient eligible for surgical clipping * patients with informed consent for inclusion into the study exclusion criteria: * patients admitted and treated \>72 h after subarachnoid hemorrhage onset * patients with severe comorbidities * patients with multiple aneurysms

Keywords: aneurysm subarachnoid hemorrhage clipping microsurgery surgery timing
a study of gefapixant (mk-7264) in adult participants with chronic cough (mk-7264-030)

Conditions: Chronic Cough

Summary: the primary objectives of this study are to evaluate the efficacy of gefapixant (mk-7264) in reducing cough frequency as measured over a 24-hour period, and to determine the safety and tolerability of gefapixant. the primary hypothesis is that at least one dose of gefapixant is superior to placebo in reducing coughs per hour (over 24 hours) at week 24.

this study will have a main 24-week treatment period and a 28-week extension period of treatment (total treatment period of 52 weeks). participants at selected sites and countries who complete the main and extension study periods may consent to participate in an observational, 12-week, off-treatment durability study period. any assessments conducted in the observational period will be exploratory.

Eligibility criteria:
inclusion criteria: * chest radiograph or computed tomography scan of the thorax (within 5 years of screening/visit 1 and after the onset of chronic cough) not demonstrating any abnormality considered to be significantly contributing to the chronic cough or any other clinically significant lung disease in the opinion of the principal investigator or the sub-investigator * has had chronic cough for at least 1 year with a diagnosis of refractory chronic cough or unexplained chronic cough * is a female who is not pregnant, not breastfeeding, not of childbearing potential, or agrees to follow contraceptive guidance * provides written informed consent and is willing and able to comply with the study protocol (including use of the digital cough recording device and completion of study questionnaires) exclusion criteria: * is a current smoker or has given up smoking within 12 months of screening, or is a former smoker with greater than 20 pack-years * has a history of respiratory tract infection or recent clinically significant change in pulmonary status * has a history of chronic bronchitis * is currently taking an angiotensin converting enzyme inhibitor (acei), or has used an acei within 3 months of screening * has an estimated glomerular filtration rate (egfr) \<30 ml/min/1.73 m\^2 at screening or an egfr ≥30 ml/min/1.73 m\^2 and \<50 ml/min/1.73 m\^2 at screening with unstable renal function * has a history of malignancy ≤5 years * is a user of recreational or illicit drugs or has had a recent history of drug or alcohol abuse or dependence * has a history of anaphylaxis or cutaneous adverse drug reaction (with or without systemic symptoms) to sulfonamide antibiotics or other sulfonamide-containing drugs * has a known allergy/sensitivity or contraindication to gefapixant * has donated or lost ≥1 unit of blood within 8 weeks prior to the first dose of gefapixant * has previously received gefapixant * currently participating in or has participated in an interventional clinical study within 30 days of screening
antiretroviral adherence evaluation in hiv pregnant and postpartum women

Conditions: HIV Infection; Pregnancy

Summary: the purpose of this study is to compare adherence to antiretroviral therapy during pregnancy and postpartum, and to record adherence barriers and facilitators.

data of all consecutive pregnant women included in the adherence enhancing program of the pharmacy, department of ambulatory care \& community medicine, are collected. in this program, adherence is measured and enhanced by electronic monitoring, pill count, motivational interviewing and interdisciplinary collaboration. electronic monitoring data are collected during pregnancy and postpartum, and compared. barriers and facilitators are collected using interview's marks.

Eligibility criteria:
inclusion criteria: * pregnant women * hiv-positive * antiretroviral medication delivered in electronical monitors exclusion criteria: * monitored period during pregnancy \< 1 month

Keywords: hiv pregnancy postpartum women medication adherence